Status:
COMPLETED
A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia
Lead Sponsor:
Novartis
Conditions:
Schizophrenia
Eligibility:
All Genders
18-64 years
Phase:
PHASE3
Brief Summary
Clozapine is an antipsychotic. This 24-week study will evaluate the safety and efficacy of clozapine in patients with treatment-resistant schizophrenia. This study is not recruiting in the United Sta...
Detailed Description
Clozapine is an antipsychotic. This 24-week study will evaluate the safety and efficacy of clozapine in patients with treatment-resistant schizophrenia.
Eligibility Criteria
Inclusion
- Diagnosed as schizophrenia
- Not responded to at least two atypical antipshychotics launched in Japan
- Inpatient
Exclusion
- Low white blood cell count
- Significant heart diseases
- Diabetes mellitus
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT00250575
Start Date
November 1 2005
Last Update
April 21 2016
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigational Site
Chiba, Japan
2
Novartis Investigative Site
Fukuoka, Japan
3
Novartis Investigative Site
Ishikawa, Japan
4
Novartis Investigative Site
Osaka, Japan